Combination Therapy with PIK3R3-siRNA and EGFR-TKI Erlotinib Synergistically Suppresses Glioblastoma Cell Growth In Vitro

CONCLUSIONS: Our data propose that suppression of PIK3R3 can effectively triggers apoptosis and enhances the sensitivity of the glioblastoma cells to EGFR-TKI erlotinib. Thus, PIK3R3 can be a potential therapeutic target in glioblastoma patients.<br />.PMID:34967581 | DOI:10.31557/APJCP.2021.22.12.3993
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Authors: Source Type: research